Literature DB >> 23143795

Heart failure determines the myocardial inflammatory response to injury.

Kirsten A Kortekaas1, Jan H Lindeman, Michel I Versteegh, Els van Beelen, Robert Kleemann, Robert J Klautz.   

Abstract

AIMS: Systemic complications after cardiac surgery are common in heart failure patients. However, the pathophysiological mechanisms, such as a different local inflammatory response of failing hearts, remain in question. This study examines whether failing hearts respond differently to cardioplegic arrest and reperfusion compared with non-failing hearts (controls). METHODS AND
RESULTS: The inflammatory response was evaluated in samples collected simultaneously from the radial artery and coronary sinus, and myocardial tissue in 62 patients undergoing cardiac surgery. No myocardial release of inflammatory mediators was observed upon reperfusion in controls (n = 19). In contrast, in patients with heart failure, reperfusion was characterized by a myocardial release of several cytokines. Myocardial interleukin-6 was 115% increased in non-ischaemic heart failure (n = 18, P = 0.002) as compared with a 117% increase in patients with ischaemic heart failure (n = 25, P = 0.01). Furthermore, a myocardial release of monocyte chemoattractant protein-1 was observed in both patient groups: a 109% (P = 0.001) and 114% (P = 0.01) increase in patients with non-ischaemic heart failure and ischaemic heart failure, respectively. Post-operative myocardial damage, expression of inflammatory mediators, and p65-nuclear factor-κB activity were similar in all patient groups. Inflammatory cell content was increased in early ischaemic myocardial tissue in both heart failure groups compared with controls.
CONCLUSION: Heart failure patients show a clear myocardial inflammatory response upon reperfusion, probably explained by degranulation of infiltrated inflammatory cells. Results in controls indicate that they better withstand cardioplegic arrest and reperfusion without an explicit myocardial inflammatory response.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23143795     DOI: 10.1093/eurjhf/hfs183

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  5 in total

1.  Pre-existing endothelial cell activation predicts vasoplegia after mitral valve surgery.

Authors:  Kirsten A Kortekaas; Jan H N Lindeman; Marlies E J Reinders; Meindert Palmen; Robert J M Klautz; Philip G de Groot; Mark Roest
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-06-04

2.  No indications for platelet activation in acute clinical myocardial or renal ischemia/reperfusion injury.

Authors:  Kirsten A Kortekaas; Dorottya K de Vries; Mark Roest; Marlies Ej Reinders; Eric P van der Veer; Robert Jm Klautz; Philip G de Groot; Alexander F Schaapherder; Jan H Lindeman
Journal:  Am J Transl Res       Date:  2018-03-15       Impact factor: 4.060

3.  Oxidative damage in clinical ischemia/reperfusion injury: a reappraisal.

Authors:  Dorottya K de Vries; Kirsten A Kortekaas; Dimitrios Tsikas; Leonie G M Wijermars; Cornelis J F van Noorden; Maria-Theresia Suchy; Christa M Cobbaert; Robert J M Klautz; Alexander F M Schaapherder; Jan H N Lindeman
Journal:  Antioxid Redox Signal       Date:  2013-03-26       Impact factor: 8.401

4.  Prevention of vasoplegia with CytoSorb in heart failure patients undergoing cardiac surgery (CytoSorb-HF trial): protocol for a randomised controlled trial.

Authors:  Olga Papazisi; Eline F Bruggemans; Remco R Berendsen; Juan D V Hugo; Jan H N Lindeman; Saskia L M A Beeres; M Sesmu Arbous; Wilbert B van den Hout; Bart J A Mertens; Can Ince; Robert J M Klautz; Meindert Palmen
Journal:  BMJ Open       Date:  2022-09-19       Impact factor: 3.006

5.  VEGF-B-induced vascular growth leads to metabolic reprogramming and ischemia resistance in the heart.

Authors:  Riikka Kivelä; Maija Bry; Marius R Robciuc; Markus Räsänen; Miia Taavitsainen; Johanna M U Silvola; Antti Saraste; Juha J Hulmi; Andrey Anisimov; Mikko I Mäyränpää; Jan H Lindeman; Lauri Eklund; Sanna Hellberg; Ruslan Hlushchuk; Zhen W Zhuang; Michael Simons; Valentin Djonov; Juhani Knuuti; Eero Mervaala; Kari Alitalo
Journal:  EMBO Mol Med       Date:  2014-01-21       Impact factor: 12.137

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.